

## Supplementary Material

# Comparative analyses of all FDA EUA-approved rapid antigen tests and RT-PCR for COVID-19 quarantine and surveillance-based isolation

Chad R. Wells<sup>1</sup>, Abhishek Pandey<sup>1</sup>, Seyed M. Moghadas<sup>2</sup>, Burton H. Singer<sup>3</sup>, Gary Krieger<sup>4,5</sup>, Richard J.L. Herron<sup>6</sup>, David E. Turner<sup>7</sup>, Justin P. Abshire<sup>8</sup>, Kimberly M. Phillips<sup>9</sup>, A. Michael Donoghue<sup>10</sup>, Alison P. Galvani<sup>1</sup>, and Jeffrey P. Townsend<sup>11,12,13,14\*</sup>

<sup>1</sup> Center for Infectious Disease Modeling and Analysis (CIDMA), Yale School of Public Health, New Haven, Connecticut, 06520, USA

<sup>2</sup> Agent-Based Modelling Laboratory, York University, Toronto, Ontario, Canada

<sup>3</sup> Emerging Pathogens Institute, University of Florida, P.O. Box 100009, Gainesville, FL 32610, USA

<sup>4</sup> NewFields E&E Boulder, Colorado 80301, USA

<sup>5</sup> Skaggs School of Pharmacy and Pharmaceutical Science, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, USA

<sup>6</sup> BP Plc, 1 ST James's Square, London, England SW1Y 4PD, UK

<sup>7</sup> BP America Inc, 501 Westlake Park Boulevard, Houston, Texas 77079, USA

<sup>8</sup> HSE Specialties, BHP Petroleum, 1500 Post Oak Blvd, Houston, Texas 77056, USA

<sup>9</sup> BHP Petroleum, 1500 Post Oak Blvd, Houston, Texas 77056, USA

<sup>10</sup> Group HSE, BHP Group Ltd., 171 Collins Street, Melbourne, Victoria 3000, Australia

<sup>11</sup> Department of Ecology and Evolutionary Biology, Yale University, New Haven, Connecticut 06525, USA

<sup>12</sup> Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut 06510, USA

<sup>13</sup> Program in Computational Biology and Bioinformatics, Yale University, New Haven, Connecticut 06511, USA

<sup>14</sup> Program in Microbiology, Yale University, New Haven, Connecticut 06511, USA

\*Corresponding author: [Jeffrey.Townsend@yale.edu](mailto:Jeffrey.Townsend@yale.edu)

## Supplementary methods

### *Quarantine and testing*

During the disease time course, the infectivity can be characterized by a functional form

$$r(t) = \begin{cases} R_0 f(t), & t \leq t_E, \\ 0, & t > t_E, \end{cases},$$

where  $f(t)$  is the relative infectivity over the course of the disease, and  $t_E$  is the duration of the disease. The average number of secondary infections in the absence of self-isolation or other interventions is then

$$R_0 = \int_0^{\infty} r(t) dt.$$

A proportion of infections  $p_A$  are asymptomatic. The remainder,  $1 - p_A$ , will develop symptoms  $t_S$  days after infection (i.e. the incubation period). For an asymptomatic individual, we assume the infectivity over time is  $r_A(t) = r(t)$ . Once an individual exhibits symptoms, they enter isolation and are assumed to no longer transmit the disease. To model the isolation of symptomatic individuals upon onset, we computed their infectivity over time as

$$r_S(t) = \begin{cases} r(t) & 0 \leq t \leq t_S, \\ 0 & t > t_S \end{cases}.$$

Individuals who manifest symptoms are not eligible for quarantine, and instead are isolated. For individuals who enter quarantine randomly over the period in which they do not exhibit symptoms, the expected post-quarantine transmission is

$$R_q^-(q) = (1 - p_A)R_{S,q}^-(q) + p_A R_{A,q}^-(q). \quad (S1)$$

The diagnostic sensitivity  $s(t)$  of a test depends on the time of testing post-infection. For a specified duration of quarantine  $q$ , number of tests administered  $N$ , delay in obtaining test result  $d_t$ , and time of testing occurring over the course of quarantine  $t_i$ , the expected post-quarantine number of secondary infections for a soon-to-be symptomatic case tested for disease at any time  $0 \leq t_n \leq q - d_t$  is

$$R_{S,q}^{-}(q) = \frac{1}{t_s} \int_{u=0}^{t_s} \int_{t=q}^{\infty} r_S(t+u) \cdot \prod_{n=1}^N (1 - s(t_n + u)) dt du. \quad (S2)$$

For asymptomatic carriers,

$$R_{A,q}^{-}(q) = \frac{1}{t_e} \int_{u=0}^{t_e} \int_{t=q}^{\infty} r(t+u) \cdot \prod_{n=1}^N (1 - s(t_n + u)) dt du. \quad (S3)$$

### *Frequency of testing to reduce the effective reproduction number*

The effective reproduction number when conducting serial testing and isolation of positives every  $\theta$  days is

$$R(\theta) = (1 - p_A)R_S(\theta) + p_A R_A(\theta). \quad (S4)$$

As individuals are not within quarantine during their surveillance, there is potential for an individual to be infected and transmit between tests. Assuming a uniform risk of infection, the probability of being infected between tests is  $1/\theta$ . For a soon-to-be symptomatic individual who will isolate upon symptom onset, the effective reproduction number with testing every  $\theta$  days is

$$R_S(\theta) = \frac{1}{\theta} \int_{\varphi=0}^{\theta} \left( \int_{t=0}^{\varphi} r_S(t) dt + \sum_{d=0}^{N_T(\theta)-2} \left( \prod_{\tau=0}^d (1 - s(\varphi + (\theta \cdot \tau))) \cdot \int_{t=\varphi+\theta d}^{\varphi+\theta(d+1)} r_S(t) dt \right) \right) d\varphi, \\ + \frac{1}{\theta} \int_{\varphi=0}^{\theta} \left( \prod_{\tau=0}^{N_T(\theta)-1} (1 - s(\varphi + (\theta \cdot \tau))) \cdot \int_{t=\varphi+\theta(N_T(\theta)-1)}^{\varphi+\theta N_T(\theta)} r_S(t) dt \right) d\varphi, \quad (S5)$$

where  $\varphi$  denotes the offset from infection to the next test (e.g., if  $\varphi = 2$ , then the initial test is conducted two-days post-infection), and  $N_T(\theta)$  denotes the number of tests conducted over the duration of disease for the specified testing frequency.

For an asymptomatic individual, the effective reproduction number with testing every  $\theta$  days and isolation of positive cases is

$$\begin{aligned}
R_A(\theta) = & \frac{1}{\theta} \int_{\varphi=0}^{\theta} \left( \int_{t=0}^{\varphi} r_A(t) dt + \sum_{d=0}^{N_T(\theta)-2} \left( \prod_{\tau=0}^d (1 - s(\varphi + (\theta \cdot \tau))) \cdot \int_{t=\varphi+\theta d}^{\varphi+\theta(d+1)} r_A(t) dt \right) \right) d\varphi. \\
& + \frac{1}{\theta} \int_{\varphi=0}^{\theta} \left( \prod_{\tau=0}^{N_T(\theta)-1} (1 - s(\varphi + (\theta \cdot \tau))) \cdot \int_{t=\varphi+\theta(N_T(\theta)-1)}^{\varphi+\theta N_T(\theta)} r_A(t) dt \right) d\varphi. \tag{S6}
\end{aligned}$$

#### *Fitting the percent positive agreement*

We estimated the coefficients of a linear logistic model

$$\ln\left(\frac{p(t)}{1-p(t)}\right) = \beta_0 + \beta_1(t - t_S) \tag{S7}$$

for the percent positive agreement  $p(t)$  between each RA test and the RT-PCR result at time  $t$  post infection. For each RA test, we fit the model to the data using a log-likelihood function  $L$ . Data on percent positive agreement for many RA tests were available from the day after symptom onset to 5–14 days after symptom onset, depending on the test. For some RA tests, the percent positive agreement with RT-PCR was calculated by aggregating results over a time span longer than a single day (e.g., 8–10 days after symptom onset). Similarly, the percent positive agreement with RT-PCR for some RA tests was specified for samples only identified as exceeding a threshold time after symptom onset (e.g., six days after symptom onset). We accounted for this heterogeneity in the format of data reporting by constructing a compound log-likelihood function

$$L = L_D + L_S + L_C \tag{S8}$$

where the log-likelihood is for the number of positive RA tests given the number of positive RT-PCR tests when reported as occurring on a specific day after symptom onset is  $L_D$ , when reported as occurring at

some point during a specified time span is  $L_S$ , and when reported as occurring on a day of or subsequent to a threshold day after symptom onset is  $L_C$ . If a set of percent positive agreement data (e.g., specific day, time span, or threshold) was absent for a rapid antigen test, then the corresponding log-likelihood term was set to zero.

The log-likelihood for the number of positive results that were obtained from the RA tests given the number of positive RT-PCR tests on a specified day after symptom onset is

$$L_D = \sum_{i=1}^N \log \left( p(t_i + t_S)^{S_i} (1 - p(t_i + t_S))^{F_i} \right), \quad (\text{S9})$$

where  $S_i$  is the number of successes at time point  $t_i$  since symptom onset (i.e., number of infected individuals testing positive for both the RA and the RT-PCR tests at time  $t_i$  since symptom onset),  $F_i$  is the number of failures (i.e., number of infected individuals testing negative for the RA test and positive for RT-PCR test at time  $t_i$  since symptom onset), and  $N$  is the number of time points.

The log-likelihood for the number of positive RA tests given the number of positive RT-PCR tests for a specified time span of days after symptom onset is

$$L_S = \sum_{j=1}^{N_S} \left( \frac{1}{1 + \tau_j - t_j} \sum_{k=t_j}^{\tau_j} \log \left( p(k + t_S)^{S_j} (1 - p(k + t_S))^{F_j} \right) \right), \quad (\text{S10})$$

where  $S_j$  is the number of successes within time span  $j$ ,  $F_j$  is the number of failures, and  $N_S$  is the number data points included in time spans,  $t_j$  is the initial time point in the time span, and  $\tau_j$  is the final time point in the time span.

The log-likelihood for the number of positive RA tests given the number of positive RT-PCR tests on or beyond a specified threshold day after symptom onset is

$$L_C = \log \left( \sum_{k=S}^T p(t + t_S)^k (1 - p(t + t_S))^{T-k} \right), \quad (\text{S11})$$

where  $t$  is the time specified for the threshold day,  $S$  is the number of successes at the threshold day, and  $T$  is the total number of tests conducted.

We stipulated a domain for  $\beta_1 < 0$ , reflecting our empirical knowledge that the RA tests become less sensitive than RT-PCR tests as the time of the case with the disease proceeds.<sup>1-3</sup>

The percent positive agreement data for all RA tests—with the exception of the BinaxNOW test—is available for days after the symptom onset either for specific days, ranges, or threshold. The BinaxNOW percent positive agreement data included six individuals that tested positive through RT-PCR on an unspecified day greater than seven days from symptom onset, three of which tested positive through the antigen test. We assumed that these samples were obtained on days not covered by the reported daily ranges of 8–10 days after symptom onset or 11–14 days after symptom onset, and thus were obtained 15 or more days after symptom onset.

None of the percent positive agreement datasets included data spanning the time prior to symptom onset. To infer the percent positive agreement during the incubation period, we constructed a mapping between the relative infectivity function,  $f(t)$ , and the percent positive agreement post-symptom onset<sup>4</sup>.

We classified the RA tests into three sensitivity categories based on temporal patterns of percent positive agreement that were i) stable, ii) gradually declining, or iii) rapidly declining. If the percent positive agreement at the time of symptom onset decreased less than 1% by 40 days after symptom onset for a test, then the test was classified as stable. A test was classified as rapid declining if the percent positive agreement was less than 1% at 20 days after symptom onset (considered the maximum duration of disease<sup>5-7</sup>). A test was classified as gradually declining if its pattern of percent positive agreement over time did not satisfy either of the criteria for relatively constant or rapid decline.

#### *False-negative for serial testing strategies*

The specificity of the RT-PCR test is 99.9%.<sup>8</sup> The specificity of RA tests is the product of the RT-PCR specificity and the negative percent agreement of the RA test (**Table S4**).

### *Diagnostic sensitivity of the RT-PCR assay*

To determine the temporal diagnostic sensitivity of the RT-PCR assay, we used data on serial testing conducted within a healthcare setting <sup>9</sup>. The corresponding data from Hellewell et al <sup>9</sup> includes symptomaticity status on the testing date, the outcome of the self-administered nasal RT-PCR test, as well as the Ct value. Serology testing was also provided in the dataset, but not utilized in our analysis. We applied the methodology of Hellewell et al <sup>9</sup>, with two exceptions: we used the distribution for the duration of the incubation period reported by Qin et al <sup>10</sup>, and we fit a log-Normal distribution for the diagnostic sensitivity function to RT-PCR test results from 27 individuals to determine its shape and scale parameters under the constraint that the timing of the peak of the logNormal distribution equaled the timing of the peak of the infectivity profile. The parameters of the diagnostic sensitivity curve of the RT-PCR assay were determined by maximizing the log-likelihood

$$L = L_T + L_P, \quad (\text{S12})$$

where  $L_T$  is the log-likelihood for the time of infection, and  $L_P$  is the log-likelihood of the RT-PCR test results.

Given the date  $t_i^L$  at which they were last asymptomatic and the date  $t_i^F$  at which they are first symptomatic, the log-likelihood for times of infection for the  $N$  individuals is

$$L_T = \sum_{i=1}^N \log\left(F(t_i^F - T_i) - F(t_i^L - T_i)\right), \quad (\text{S13})$$

where  $F$  is the cumulative distribution of the incubation period. This log-likelihood accounts for the censoring of the time symptoms appeared between the testing times to determine the time of infection <sup>9</sup>.

For the specified diagnostic sensitivity of the test for all individuals and  $M_i$  tests for individual  $i$ , the likelihood for the test result is expressed by

$$L_P = \sum_{i=1}^N \sum_{j=1}^{M_i} \log\left(s(x_{i,j})^{R_{i,j}} (1 - s(x_{i,j}))^{1-R_{i,j}}\right), \quad (\text{S14})$$

where  $R_{i,j}$  is the result of test  $j$  for individual  $i$  (if the test is positive then  $R_{i,j} = 1$ ; otherwise,  $R_{i,j} = 0$ ), and

$s(t)$  is the diagnostic sensitivity at time  $t$  post-infection.

To estimate the time of infection, we specified the upper bound for the time of infection for an individual to be the minimum of the day of their first positive test, their first day of symptoms, and their first day of a non-zero cycle threshold. The corresponding lower bound was set to 30 days prior to this data-driven upper bound.

The two main differences between the method of Hellewell et al <sup>9</sup> and our approach are the distribution of the incubation period and the function for the diagnostic sensitivity. The inference from Hellewell et al <sup>9</sup> applies the distribution of the incubation period from Lauer et al <sup>11</sup>, which has a mean of 5.5 days, while we estimate the time of infection based on the distribution reported by Qin et al <sup>10</sup>—with corresponding mean of 8.29 days. For the diagnostic sensitivity, Hellewell et al <sup>9</sup> used a piecewise logistic regression. Here we modeled the diagnostic sensitivity using the probability density function of a log-Normal distribution. Denoting the scaling coefficient as  $C$ , the shape coefficient as  $z$ , and the coefficient determining peak diagnostic sensitivity as  $K$ , we quantified the continuous probability that the RT-PCR test is positive given a sample from an infected patient (i.e., diagnostic sensitivity) at time  $t$  with the log-Normal probability density function

$$s(t) = \frac{C}{tz\sqrt{2\pi}} \exp\left\{-\frac{(\log(t)-K)^2}{2z^2}\right\}, \quad (\text{S15})$$

where  $s(0) = 0$ . To obtain the criterion that the diagnostic sensitivity peaks at the same time as the infectivity profile, we calculated the coefficient determining peak diagnostic sensitivity

$$K = \ln(t_p) + z^2, \quad (\text{S16})$$

where  $t_p$  is the time of the peak in the infectivity profile and  $z$  is estimated in the model fitting.





• Indicates that there was no data available for the specified time period

<sup>a</sup> Peer-reviewed

<sup>b</sup> Data from EUA submission

<sup>c</sup> Anterior nasal swab

<sup>d</sup> Data from community testing

<sup>e</sup> Nasopharyngeal swab

<sup>f</sup> Mid-turbinate swab

**Table S2.** Estimated coefficients for the logistic regression models describing the percent positive agreement curve for each of the rapid antigen tests

Test name	$\beta_0$	$\beta_1$
BD Veritor <sup>a,b,c</sup>	2.55	- 0.38
BinaxNOW <sup>b,c</sup>	1.95	- 0.10
BinaxNOW <sup>c,d</sup>	2.91	- $3.85 \times 10^{-10}$
BinaxNOW <sup>c,e</sup>	2.50	- 0.15
CareStart <sup>b,c</sup>	2.20	- 0.12
CareStart <sup>b,f</sup>	6.77	- 1.00
CareStart <sup>c,d</sup>	1.87	- $4.37 \times 10^{-10}$
CareStart <sup>c,e</sup>	1.89	- $4.90 \times 10^{-10}$
Celltrion DiaTrust <sup>b,f</sup>	4.81	- 0.52
Clip COVID <sup>b,c</sup>	3.43	- $1.28 \times 10^{-10}$
Ellume <sup>b,g</sup>	100	- 15.31
Liaison <sup>b,c</sup>	3.47	- $1.15 \times 10^{-9}$
Liaison <sup>b,f</sup>	3.20	- $1.73 \times 10^{-9}$
LumiraDx <sup>b,c</sup>	5.64	- 0.33
LumiraDx <sup>b,f</sup>	12.09	- 1.05
Omnia <sup>b,c</sup>	2.14	- $9.05 \times 10^{-9}$
SCoV-2 <sup>b,c</sup>	2.03	- 0.05
Simoa <sup>b,f</sup>	4.17	- 0.08

Sofia <sup>b,c</sup>	3.37	- $2.22 \times 10^{-8}$
Sofia <sup>c,d</sup>	1.35	- $9.23 \times 10^{-10}$
Sofia <sup>c,e</sup>	1.90	- $8.98 \times 10^{-10}$
Sofia 2 Flu + SARS <sup>b,c</sup>	4.77	- 0.60
Status COVID + Flu <sup>b,f</sup>	2.93	- 0.14
Vitros <sup>b,f</sup>	1.39	- $8.00 \times 10^{-10}$

---

<sup>a</sup> Peer-reviewed EUA data

<sup>b</sup> Data from EUA submission

<sup>c</sup> Anterior nasal swab

<sup>d</sup> Data from community testing

<sup>e</sup> Data from EUA submission and community testing

<sup>f</sup> Nasopharyngeal swab

<sup>g</sup> Mid-turbinate swab

**Table S3.** Required quarantine durations, serial testing frequencies, and probabilities of false-positives.

Rapid antigen test	RT-PCR sensitivity based on Hellewell et al <sup>9</sup>				RT-PCR sensitivity based on Wells et al <sup>4</sup>			
	Quarantine required		Serial testing required		Quarantine required		Serial testing required	
	Exit test <sup>a</sup>	Entry and exit test <sup>a</sup>	Frequency <sup>b</sup>	Prob. of a false positive <sup>c</sup>	Exit test <sup>a</sup>	Entry and exit test <sup>a</sup>	Frequency <sup>b</sup>	Prob. of a false positive <sup>c</sup>
BD Veritor <sup>d,e</sup>	12	11	6	0.013	13	12	8	0.01
BinaxNOW <sup>e,f</sup>	11	10	7	0.031	12	10	9	0.024
BinaxNOW <sup>g,f</sup>	11	7	8	0.012	9	8	11	0.009
BinaxNOW <sup>h,f</sup>	11	8	7	0.016	11	9	9	0.013
CareStart <sup>e,f</sup>	11	10	7	0.002	11	9	9	0.002
CareStart <sup>e,i</sup>	11	6	7	0.015	13	7	9	0.012
CareStart <sup>f,g</sup>	11	10	7	0.035	11	9	10	0.024
CareStart <sup>f,h</sup>	11	10	7	0.034	11	9	10	0.024
Celltrion DiaTrust <sup>e,i</sup>	11	6	7	0.021	11	7	9	0.017
Clip COVID <sup>e,f</sup>	11	6	8	0.002	9	7	11	0.001
Ellume <sup>e,j</sup>	11	6	7	0.063	12	7	9	0.049
Liaison <sup>e,f</sup>	11	6	8	0.002	9	7	11	0.001
Liaison <sup>e,i</sup>	11	7	8	0.015	9	8	11	0.011
LumiraDX <sup>e,f</sup>	11	6	8	0.061	8	7	11	0.045
LumiraDX <sup>e,i</sup>	11	6	8	0.042	8	7	10	0.034
Omnia <sup>e,f</sup>	11	9	7	0.002	11	9	10	0.001
SCoV-2 <sup>e,f</sup>	11	10	7	0.002	11	9	10	0.001
Simoa <sup>e,i</sup>	11	6	8	0.002	8	7	11	0.001
Sofia <sup>e,f</sup>	11	7	8	0.002	9	8	11	0.001
Sofia <sup>h,f</sup>	12	10	6	0.038	12	11	9	0.025
Sofia <sup>g,f</sup>	11	10	7	0.028	11	9	10	0.02

Sofia 2 Flu+SARS <sup>e,f</sup>	11	6	7	0.002	12	7	9	0.002
Status COVID+Flu <sub>e,i</sub>	11	7	7	0.002	10	8	10	0.001
Vitros <sup>e,i</sup>	12	10	6	0.002	12	10	9	0.002

<sup>a</sup> Quarantine durations that are equivalent or better than a 7-day quarantine with an RT-PCR test conducted 24 h before exit.

<sup>b</sup> The minimum required testing frequency for serial testing such that the effective reproductive number is less than one.

<sup>c</sup> The probability of at least one false positive in a two-week period of serial testing under the minimum required testing frequency.

<sup>d</sup> Peer-reviewed

<sup>e</sup> Data from EUA submission

<sup>f</sup> Anterior nasal swab

<sup>g</sup> Data from community testing

<sup>h</sup> Combined data from EUA submission and community testing

<sup>i</sup> Nasopharyngeal swab

<sup>j</sup> Mid-turbinate swab

**Table S4.** The specificity of the EUA rapid antigen tests considered in the analysis.

Test	Fraction of RA tests in agreement with negative RT-PCR	Specificity	Data Source	Reference
RT-PCR	N/A	99.90% (12392/12404)	Community testing	8
BD Veritor <sup>a</sup>	212/213	99.43%	EUA submission <sup>b</sup>	12
BinaxNOW <sup>a</sup>	338/343	98.45%	EUA submission	13
BinaxNOW <sup>a</sup>	2004/2016 <sup>c</sup>	99.31%	Community testing	14
BinaxNOW <sup>a</sup>	2342/2359	99.18%	EUA submission and community testing	13,14
CareStart <sup>a</sup>	53/53	99.90%	EUA submission	15
CareStart <sup>d</sup>	147/148	99.23%	EUA submission	15
CareStart <sup>a</sup>	1243/1264 <sup>c</sup>	98.24%	Community testing	16
CareStart <sup>a</sup>	1296/1317	98.31%	EUA submission and community testing	15,16
Celltrion <sup>d</sup>	102/103	98.93%	EUA submission	17
Clip COVID <sup>a</sup>	134/134	99.90%	EUA submission	18
Ellume <sup>c</sup>	156/161 <sup>c</sup>	96.80%	EUA submission	19
Liaison <sup>a</sup>	108/108	99.90%	EUA submission	20
Liaison <sup>d</sup>	133/134	99.16%	EUA submission	20
LumiraDx <sup>a</sup>	168/174	96.46%	EUA submission	21
LumiraDx <sup>d</sup>	210/215	97.58%	EUA submission	22
Omnia <sup>a</sup>	32/32	99.90%	EUA submission	23
SCoV-2 <sup>a</sup>	257/257	99.90%	EUA submission	24
Simoa <sup>d</sup>	38/38	99.90%	EUA submission	25
Sofia <sup>a</sup>	179/179	99.90%	EUA submission	26

Sofia <sup>a</sup>	1025/1041 <sup>c</sup>	98.37%	Community testing	27
Sofia <sup>a</sup>	1204/1220	98.59%	EUA submission and community testing	26,27
Sofia 2 Flu + SARS <sup>a</sup>	122/122	99.90%	EUA submission	28
Status COVID/Flu <sup>d</sup>	76/76	99.90%	EUA submission	29
VITROS <sup>d</sup>	75/75	99.90%	EUA submission	30

<sup>a</sup> Anterior nasal swab

<sup>b</sup> Peer-reviewed EUA data

<sup>c</sup> Calculated based on both symptomatic and asymptomatic individuals

<sup>d</sup> Nasopharyngeal swab

<sup>e</sup> Mid-turbinate swab


**Table S5. Cycle times in rapid antigen test false negatives and true positives**

Paired sampling outcome	Day of quarantine	Gene		
		<i>N</i>	ORF1ab	<i>S</i>
<i>RA - / RT-PCR +</i>				
Sample 1	0	31	30	32
Sample 2	0	32	31	30
Sample 3	0	28	28	28
Sample 4	0	30	31	36
Sample 5	0	32	34	— <sup>a</sup>
Sample 6	0	24	22	23
Sample 7	0	32	31	35
Sample 8	0	32	0 <sup>a</sup>	0 <sup>a</sup>
Sample 9	0	30	33	34
Sample 10	3	32	30	— <sup>a</sup>
Sample 11	3	30	30	31
Sample 12	3	29	28	28
Sample 13	3	— <sup>a</sup>	31	33
Sample 14	4	32	31	33
Sample 15	4	27	25	26
Sample 16	4	33	— <sup>a</sup>	— <sup>a</sup>
<i>RA + / RT-PCR +</i>				
Sample 1	0	17	17	18
Sample 2	0	— <sup>a</sup>	34	34
Sample 3	0	19	18	18
Sample 4	3	13	11	12


<sup>a</sup> Result was negative (cycle time threshold: >36)




## Supplementary figures




**Figure S1. The diagnostic sensitivity curve and probability of post-quarantine transmission for LumiraDx.** Specifying an 8.29-day incubation period, 30.8% of infections being asymptomatic, self-isolation upon symptom onset, **(A)** the RT-PCR diagnostic sensitivity curve (black) informed by data from Hellewell et al <sup>9</sup>, and logistic regression model for the diagnostic sensitivity of the rapid antigen test for anterior nasal swab (blue, solid line) and nasopharyngeal swab (yellow, dashed line) informed by percent positive agreement data (anterior nasal swab: blue triangles; nasopharyngeal swab: yellow hexagons); **(B)** the probability of post-quarantine transmission for a RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled blue triangles and filled yellow hexagons), as well as a rapid antigen test conducted on both entry to and exit from quarantine (open blue triangles and open yellow hexagons, dashed line); **(C)** the diagnostic sensitivity of the rapid antigen test specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>; **(D)** the probability of post-quarantine transmission when requiring an RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled blue triangles and filled yellow hexagons), and a rapid antigen test conducted on both entry to and exit from quarantine (open blue triangles and open yellow hexagons, dashed line), specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>.




**Figure S2. The diagnostic sensitivity curve and probability of post-quarantine transmission for Sofia.** Specifying an 8.29-day incubation period, 30.8% of infections being asymptomatic, self-isolation upon symptom onset, (A) the RT-PCR diagnostic sensitivity curve (black) informed by data from Hellewell et al <sup>9</sup>, and logistic regression model for the diagnostic sensitivity of the rapid antigen test (green, solid line) informed by percent positive agreement data (green squares); (B) the probability of post-quarantine transmission for a RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled green squares), as well as a rapid antigen test conducted on both entry to and exit from quarantine (open green squares, dashed line); (C) the diagnostic sensitivity of the rapid antigen test specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>; (D) the probability of post-quarantine transmission when requiring an RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled green squares), and a rapid antigen test conducted on both entry to and exit from quarantine (open green squares, dashed line), specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>.







**Figure S4. The diagnostic sensitivity curve and probability of post-quarantine transmission for BD Veritor.** Specifying an 8.29-day incubation period, 30.8% of infections being asymptomatic, self-isolation upon symptom onset, **(A)** the RT-PCR diagnostic sensitivity curve (black) informed by data from Hellewell et al <sup>9</sup>, and logistic regression model for the diagnostic sensitivity of the rapid antigen test (dark orange, solid line) informed by percent positive agreement data (dark orange triangles); **(B)** the probability of post-quarantine transmission for a RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled dark orange triangles), as well as a rapid antigen test conducted on both entry to and exit from quarantine (open dark orange triangles, dashed line); **(C)** the diagnostic sensitivity of the rapid antigen test specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>; **(D)** the probability of post-quarantine transmission when requiring an RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled dark orange triangles), and a rapid antigen test conducted on both entry to and exit from quarantine (open dark orange triangles, dashed line), specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>.




**Figure S5. The diagnostic sensitivity curve and probability of post-quarantine transmission for Celltrion DiaTrust.** Specifying an 8.29-day incubation period, 30.8% of infections being asymptomatic, self-isolation upon symptom onset, **(A)** the RT-PCR diagnostic sensitivity curve (black) informed by data from Hellewell et al <sup>9</sup>, and logistic regression model for the diagnostic sensitivity of the rapid antigen test (yellow, solid line) informed by percent positive agreement data (yellow triangles); **(B)** the probability of post-quarantine transmission for a RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled yellow triangles), as well as a rapid antigen test conducted on both entry to and exit from quarantine (open yellow triangles, dashed line); **(C)** the diagnostic sensitivity of the rapid antigen test specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>; **(D)** the probability of post-quarantine transmission when requiring an RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled yellow triangles), and a rapid antigen test conducted on both entry to and exit from quarantine (open yellow triangles, dashed line), specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>.



**Figure S6. The diagnostic sensitivity curve and probability of post-quarantine transmission for CareStart.** Specifying an 8.29-day incubation period, 30.8% of infections being asymptomatic, self-isolation upon symptom onset, **(A)** the RT-PCR diagnostic sensitivity curve (black) informed by data from Hellewell et al <sup>9</sup>, and logistic regression model for the diagnostic sensitivity of the rapid antigen test for anterior nasal swab (purple, solid line) and nasopharyngeal swab (orange, dashed line) informed by percent positive agreement data (anterior nasal swabs: purple hexagams; nasopharyngeal swab: orange circles); **(B)** the probability of post-quarantine transmission for a RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled purple hexagams and filled orange circles), as well as a rapid antigen test conducted on both entry to and exit from quarantine (open purple hexagams and open orange circles, dashed line); **(C)** the diagnostic sensitivity of the rapid antigen test specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>; **(D)** the probability of post-quarantine transmission when requiring an RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled purple hexagams and filled orange circles), and a rapid antigen test conducted on both entry to and exit from quarantine (open purple hexagams and open orange circles, dashed line), specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>.




**Figure S7. The diagnostic sensitivity curve and probability of post-quarantine transmission for Clip COVID.** Specifying an 8.29-day incubation period, 30.8% of infections being asymptomatic, self-isolation upon symptom onset, **(A)** the RT-PCR diagnostic sensitivity curve (black) informed by data from Hellewell et al <sup>9</sup>, and logistic regression model for the diagnostic sensitivity of the rapid antigen test (light green, solid line) informed by percent positive agreement data (light green triangles); **(B)** the probability of post-quarantine transmission for a RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled light green triangles), as well as a rapid antigen test conducted on both entry to and exit from quarantine (open light green triangles, dashed line); **(C)** the diagnostic sensitivity of the rapid antigen test specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>; **(D)** the probability of post-quarantine transmission when requiring an RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled light green triangles), and a rapid antigen test conducted on both entry to and exit from quarantine (open light green triangles, dashed line), specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>.




**Figure S8. The diagnostic sensitivity curve and probability of post-quarantine transmission for Liaison.** Specifying an 8.29-day incubation period, 30.8% of infections being asymptomatic, self-isolation upon symptom onset, **(A)** the RT-PCR diagnostic sensitivity curve (black) informed by data from Hellewell et al <sup>9</sup>, and logistic regression model for the diagnostic sensitivity of the rapid antigen test for anterior nasal swab (green, solid line) and nasopharyngeal swab (green, dashed line) informed by percent positive agreement data (anterior nasal swab: green triangles; nasopharyngeal swab: green hexagrams); **(B)** the probability of post-quarantine transmission for a RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled green triangles and filled green hexagrams), as well as a rapid antigen test conducted on both entry to and exit from quarantine (open green triangles and open green hexagrams, dashed line); **(C)** the diagnostic sensitivity of the rapid antigen test specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>; **(D)** the probability of post-quarantine transmission when requiring an RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled green triangles and filled green hexagrams), and a rapid antigen test conducted on both entry to and exit from quarantine (open green triangles and open green hexagrams, dashed line), specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>.







**Figure S9. The diagnostic sensitivity curve and probability of post-quarantine transmission for Omnia.** Specifying an 8.29-day incubation period, 30.8% of infections being asymptomatic, self-isolation upon symptom onset, (A) the RT-PCR diagnostic sensitivity curve (black) informed by data from Hellewell et al <sup>9</sup>, and logistic regression model for the diagnostic sensitivity of the rapid antigen test (green, solid line) informed by percent positive agreement data (green triangles); (B) the probability of post-quarantine transmission for a RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled green triangles), as well as a rapid antigen test conducted on both entry to and exit from quarantine (open green triangles, dashed line); (C) the diagnostic sensitivity of the rapid antigen test specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>; (D) the probability of post-quarantine transmission when requiring an RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled green triangles), and a rapid antigen test conducted on both entry to and exit from quarantine (open green triangles, dashed line), specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>.




**Figure S10. The diagnostic sensitivity curve and probability of post-quarantine transmission for SCoV-2.** Specifying an 8.29-day incubation period, 30.8% of infections being asymptomatic, self-isolation upon symptom onset, (A) the RT-PCR diagnostic sensitivity curve (black) informed by data from Hellewell et al<sup>9</sup>, and logistic regression model for the diagnostic sensitivity of the rapid antigen test (purple, solid line) informed by percent positive agreement data (purple triangles); (B) the probability of post-quarantine transmission for a RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled purple triangles), as well as a rapid antigen test conducted on both entry to and exit from quarantine (open purple triangles, dashed line); (C) the diagnostic sensitivity of the rapid antigen test specifying the RT-PCR diagnostic sensitivity curve from Wells et al<sup>4</sup>; (D) the probability of post-quarantine transmission when requiring an RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled purple triangles), and a rapid antigen test conducted on both entry to and exit from quarantine (open purple triangles, dashed line), specifying the RT-PCR diagnostic sensitivity curve from Wells et al<sup>4</sup>.




**Figure S11. The diagnostic sensitivity curve and probability of post-quarantine transmission for Simoa.** Specifying an 8.29-day incubation period, 30.8% of infections being asymptomatic, self-isolation upon symptom onset, **(A)** the RT-PCR diagnostic sensitivity curve (black) informed by data from Hellewell et al <sup>9</sup>, and logistic regression model for the diagnostic sensitivity of the rapid antigen test (light blue, solid line) informed by percent positive agreement data (light blue circles); **(B)** the probability of post-quarantine transmission for a RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled light blue circles), as well as a rapid antigen test conducted on both entry to and exit from quarantine (open light blue circles, dashed line); **(C)** the diagnostic sensitivity of the rapid antigen test specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>; **(D)** the probability of post-quarantine transmission when requiring an RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled light blue circles), and a rapid antigen test conducted on both entry to and exit from quarantine (open light blue circles, dashed line), specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>.




**Figure S12. The diagnostic sensitivity curve and probability of post-quarantine transmission for Status COVID + Flu.** Specifying an 8.29-day incubation period, 30.8% of infections being asymptomatic, self-isolation upon symptom onset, **(A)** the RT-PCR diagnostic sensitivity curve (black) informed by data from Hellewell et al <sup>9</sup>, and logistic regression model for the diagnostic sensitivity of the rapid antigen test (purple, solid line) informed by percent positive agreement data (purple triangles); **(B)** the probability of post-quarantine transmission for a RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled purple triangles), as well as a rapid antigen test conducted on both entry to and exit from quarantine (open purple triangles, dashed line); **(C)** the diagnostic sensitivity of the rapid antigen test specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup> **(D)** the probability of post-quarantine transmission when requiring an RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled purple triangles), and a rapid antigen test conducted on both entry to and exit from quarantine (open purple triangles, dashed line), specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>.




**Figure S13. The diagnostic sensitivity curve and probability of post-quarantine transmission for Vitros.** Specifying an 8.29-day incubation period, 30.8% of infections being asymptomatic, self-isolation upon symptom onset, **(A)** the RT-PCR diagnostic sensitivity curve (black) informed by data from Hellewell et al <sup>9</sup>, and logistic regression model for the diagnostic sensitivity of the rapid antigen test (green, solid line) informed by percent positive agreement data (green diamonds); **(B)** the probability of post-quarantine transmission for a RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled green diamonds), as well as a rapid antigen test conducted on both entry to and exit from quarantine (open green diamonds, dashed line); **(C)** the diagnostic sensitivity of the rapid antigen test specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>; **(D)** the probability of post-quarantine transmission when requiring an RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled green diamonds), and a rapid antigen test conducted on both entry to and exit from quarantine (open green diamonds, dashed line), specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>.



**Figure S14. The diagnostic sensitivity curve and probability of post-quarantine transmission for Sofia 2 Flu + SARS.** Specifying an 8.29-day incubation period, 30.8% of infections being asymptomatic, self-isolation upon symptom onset, **(A)** the RT-PCR diagnostic sensitivity curve (black) informed by data from Hellewell et al <sup>9</sup>, and logistic regression model for the diagnostic sensitivity of the rapid antigen test (dark orange, solid line) informed by percent positive agreement data (dark orange diamonds); **(B)** the probability of post-quarantine transmission for a RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled dark orange diamonds), as well as a rapid antigen test conducted on both entry to and exit from quarantine (open dark orange diamonds, dashed line); **(C)** the diagnostic sensitivity of the rapid antigen test specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>; **(D)** the probability of post-quarantine transmission when requiring an RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled dark orange diamonds), and a rapid antigen test conducted on both entry to and exit from quarantine (open dark orange diamonds, dashed line), specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>.




**Figure S15. The diagnostic sensitivity curve and probability of post-quarantine transmission for Ellume.** Specifying an 8.29-day incubation period, 30.8% of infections being asymptomatic, self-isolation upon symptom onset, **(A)** the RT-PCR diagnostic sensitivity curve (black) informed by data from Hellewell et al<sup>9</sup>, and logistic regression model for the diagnostic sensitivity of the rapid antigen test (dark yellow solid line) informed by percent positive agreement data (dark yellow squares); **(B)** the probability of post-quarantine transmission for a RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled dark yellow squares), as well as a rapid antigen test conducted on both entry to and exit from quarantine (open dark yellow squares, dashed line); **(C)** the diagnostic sensitivity of the rapid antigen test specifying the RT-PCR diagnostic sensitivity curve from Wells et al<sup>4</sup>; **(D)** the probability of post-quarantine transmission when requiring an RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled dark yellow squares), and a rapid antigen test conducted on both entry to and exit from quarantine (open dark yellow squares, dashed line), specifying the RT-PCR diagnostic sensitivity curve from Wells et al<sup>4</sup>.




**Figure S16. The diagnostic sensitivity curve and probability of post-quarantine transmission for the internal and external percent positive agreement data for Sofia.** Specifying a 8.29 day, 30.8% of infections being asymptomatic, self-isolation upon symptom onset, (A) the RT-PCR diagnostic sensitivity curve (black) informed by data from Hellewell et al <sup>9</sup>, and logistic regression model for the diagnostic sensitivity of the rapid antigen test for the internal data set (blue, solid line) and the external data set (pink, dashed line) informed by percent positive agreement data (internal: blue circles; external: pink diamonds); (B) the probability of post-quarantine transmission for a RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled blue circles and filled pink diamonds), as well as a rapid antigen test conducted on both entry to and exit from quarantine (open blue circles and open pink diamonds, dashed line); (C) the diagnostic sensitivity of the rapid antigen test specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>; (D) the probability of post-quarantine transmission when requiring an RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled blue circles and filled pink diamonds), as well as a rapid antigen test conducted on both entry to and exit from quarantine (open blue circles and open pink diamonds, dashed line), specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>.







**Figure S17. The diagnostic sensitivity curve and probability of post-quarantine transmission for the industrial and external percent positive agreement data for CareStart.** Specifying a 8.29 day, 30.8% of infections being asymptomatic, self-isolation upon symptom onset, **(A)** the RT-PCR diagnostic sensitivity curve (black) informed by data from Hellewell et al <sup>9</sup>, and logistic regression model for the diagnostic sensitivity of the rapid antigen test for the internal data set (blue, solid line) and the external data set (purple, dashed line) informed by percent positive agreement data (internal: blue circles; external: purple squares); **(B)** the probability of post-quarantine transmission for a RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled blue circles and filled purple squares), as well as a rapid antigen test conducted on both entry to and exit from quarantine (open blue circles and open purple squares, dashed line); **(C)** the diagnostic sensitivity of the rapid antigen test specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>; **(D)** the probability of post-quarantine transmission when requiring an RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled blue circles and filled purple squares), as well as a rapid antigen test conducted on both entry to and exit from quarantine (open blue circles and open purple squares, dashed line), specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>.




**Figure S18. The diagnostic sensitivity curve and probability of post-quarantine transmission for the industrial and external percent positive agreement data for BinaxNOW.** Specifying a 8.29 day, 30.8% of infections being asymptomatic, self-isolation upon symptom onset, **(A)** the RT-PCR diagnostic sensitivity curve (black) informed by data from Hellewell et al <sup>9</sup>, and logistic regression model for the diagnostic sensitivity of the rapid antigen test for the internal data set (blue, solid line) and the external data set (red, dashed line) informed by percent positive agreement data (internal: blue squares; external: red circles); **(B)** the probability of post-quarantine transmission for a RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled blue squares and filled red circles), as well as a rapid antigen test conducted on both entry to and exit from quarantine (open blue squares and open purple circles, dashed line); **(C)** the diagnostic sensitivity of the rapid antigen test specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>; **(D)** the probability of post-quarantine transmission when requiring an RT-PCR test conducted 24 h before exit from quarantine (black stars), a rapid antigen test on exit (filled blue squares and filled red circles), as well as a rapid antigen test conducted on both entry to and exit from quarantine (open blue squares and open red circles, dashed line), specifying the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>.




**Figure S19. The effective reproduction number when serial testing is conducted once every five to eight days with a rapid antigen test or RT-PCR.** Specifying an 8.29-day incubation period, 30.8% of infections as asymptomatic, a one day delay in receiving RT-PCR and rapid antigen test results, self-isolation upon symptom onset, and the RT-PCR diagnostic sensitivity curve informed by data from Hellewell et al <sup>9</sup>, the expected transmission with serial testing using an RT-PCR test (black) and the 18 rapid antigen tests (colours; x axis) when testing is conducted (A) every nine days, (B) every eight days, (C) every seven days, and (D) every six days.




**Figure S20. The effective reproduction number, and probability of a false positive, for a range of frequencies of serial testing with RT-PCR and rapid antigen tests.** Specifying an 8.29-day incubation period, 30.8% of infections being asymptomatic, a 24-h delay in receiving RT-PCR test results, and no-delay rapid antigen test results, self-isolation upon symptom onset, and the diagnostic sensitivity curve for the RT-PCR was informed by data from Hellewell et al <sup>9</sup>, the expected transmission with serial testing using an RT-PCR test with a one-day delay in obtaining test results (black stars) and the 18 rapid antigen tests (colours) for testing every day to every 14 days (small dots: longer time between tests; larger dots: shorter time between tests) and the corresponding probability of at least one false positive over a two-week period (x axis).




**Figure S21: Diagnostic sensitivity of RT-PCR and rapid antigen tests.** Specifying an incubation period of 8.29 days and the diagnostic sensitivity curve for the RT-PCR from Wells et al <sup>4</sup>, the estimated diagnostic sensitivity of RT-PCR tests (black stars) and rapid antigen tests LumiraDx (blue squares); Sofia (green diamonds); BinaxNOW (yellow triangles); BD Veritor (red circles); CareStart (purple hexagams) over the course of infection.



**Figure S22. Probability of post-quarantine transmission and fraction of antigen tests outperforming RT-PCR for quarantines of one to 14 days based on an alternative diagnostic sensitivity function.** Specifying a negative-binomial distribution for expected post-quarantine transmission, 30.8% of infections being asymptomatic, a 24-h delay in obtaining RT-PCR test results, a negligible delay in receiving rapid antigen test results, an incubation period of 8.29 days, self-isolation upon symptom onset, and the diagnostic sensitivity curve from Wells et al <sup>4</sup>, the probability of post-quarantine transmission when conducting an RT-PCR test only on exit (solid line; black stars) and the rapid antigen tests (dashed lines) LumiraDx (blue squares); Sofia (green diamonds); BinaxNOW (yellow triangles); and BD Veritor (red circles) performed on (A) exit and (B) both entry and exit; and the fraction of the 18 rapid antigen tests whose use conferred a lower probability of post-quarantine transmission than did an RT-PCR test conducted 24 h before exit from quarantine, when the rapid antigen test was conducted (C) on exit and (D) on both entry and exit.




**Figure S23. Effective reproduction number with frequencies of serial testing from every day to every 14 days and isolation of positives, based on an alternative diagnostic sensitivity function.** Specifying 30.8% of infections as asymptomatic, a one day delay in receiving RT-PCR and rapid antigen test results, an incubation period of 8.29 days, self-isolation upon symptom onset, and a RT-PCR diagnostic sensitivity curve from Wells et al. <sup>4</sup> (A) the expected effective reproduction number with serial testing using an RT-PCR test (black) and the rapid antigen tests LumiraDx (blue); Sofia (green); BinaxNOW (yellow); and BD Veritor (red), and (B) for serial testing every day to every 14 days with a zero- to five-day delay (black to light gray) in obtaining the results for an RT-PCR test and isolation of positives in comparison to no testing (solid gray line). (C) The fraction of rapid antigen tests of the 18 tests that had a lower effective reproduction number than a RT-PCR test with a 24-h delay, and (D) that had an effective reproduction number ( $R_E$ ) below one for testing frequencies ranging from every day to every two weeks and isolating positives.




**Figure S24. Effective reproduction numbers and probabilities of false positives for varying frequencies of serial testing with RT-PCR and rapid antigen tests and isolation of positives, based on an alternative diagnostic sensitivity function.** Specifying 30.8% of infections being asymptomatic, a negligible delay in receiving RT-PCR and rapid antigen test results, an incubation period of 8.29 days, self-isolation upon symptom onset, and the diagnostic sensitivity curve for the RT-PCR from Wells et al <sup>4</sup>, the expected transmission with serial RT-PCR testing with a zero- to five-day delay (black star gradient) in obtaining test results, and the rapid antigen test LumiraDx (blue square); Sofia (green diamond); BinaxNOW (yellow triangle); BD Veritor (red circle); and CareStart (purple hexagram) for testing every day to every 14 days (small dots: longer time between tests; larger dots: shorter time between tests) and the corresponding probability of at least one false positive over a two-week period (x axis).





**Figure S25. The effective reproduction number when serial testing is conducted once each seven to twelve days with a rapid antigen test or RT-PCR for an alternative diagnostic sensitivity function.** Specifying an 8.29-day incubation period, 30.8% of infections as asymptomatic, a one-day delay in receiving RT-PCR and rapid antigen test results, self-isolation upon symptom onset, and the RT-PCR diagnostic sensitivity curve from Wells et al <sup>4</sup>, the expected transmission with serial testing using an RT-PCR test (black) and the 18 rapid antigen tests (colours; x axis) when testing is conducted (A) every 12 days, (B) every 11 days, (C) every 10 days, (D) every nine days, (E) every eight days, and (F) every seven days.



**Figure S26. The effective reproduction number, and probability of a false positive, for a range of frequencies of serial testing with RT-PCR and rapid antigen tests for an alternative diagnostic sensitivity function.** Specifying an 8.29-day incubation period, 30.8% of infections being asymptomatic, a 24-h delay in receiving RT-PCR test results, and no-delay rapid antigen test results, self-isolation upon symptom onset, and the diagnostic sensitivity curve for the RT-PCR was informed by data from Wells et al <sup>4</sup>, the expected transmission with serial testing using an RT-PCR test with a one-day delay in obtaining test results (black stars) and the 18 rapid antigen tests (colours) for testing every day to every 14 days (small symbols: longer time between tests; larger symbols: shorter time between tests) and the corresponding probability of at least one false positive over a two-week period (x axis).

## References cited in supplementary material

1. CDC. Overview of Testing for SARS-CoV-2 (COVID-19).  
<https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html> (2021).
2. Salvagno, G. L., Gianfilippi, G., Bragantini, D., Henry, B. M. & Lippi, G. Clinical assessment of the Roche SARS-CoV-2 rapid antigen test. *Acta Radiol. Diagn.* (2021) doi:10.1515/dx-2020-0154.
3. Guglielmi, G. Fast coronavirus tests: what they can and can't do. *Nature* **585**, 496–498 (2020).
4. Wells, C. R. *et al.* Optimal COVID-19 quarantine and testing strategies. *Nat. Commun.* **12**, 356 (2021).
5. Xiao, A. T. *et al.* Dynamic Profile of RT-PCR Findings from 301 COVID-19 Patients in Wuhan, China: A Descriptive Study. *SSRN Electronic Journal* doi:10.2139/ssrn.3548769.
6. CDC. Interim Guidance on Duration of Isolation and Precautions for Adults with COVID-19.  
<https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html> (2021).
7. Cevik, M. *et al.* SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. *Lancet Microbe* **2**, e13–e22 (2021).
8. Hogan, C. A. *et al.* Large-Scale Testing of Asymptomatic Healthcare Personnel for Severe Acute Respiratory Syndrome Coronavirus 2 - Volume 27, Number 1—January 2021 - Emerging Infectious Diseases journal - CDC. doi:10.3201/eid2701.203892.
9. Hellewell, J. *et al.* Estimating the effectiveness of routine asymptomatic PCR testing at different frequencies for the detection of SARS-CoV-2 infections. *BMC Medicine* **19**, (2021).
10. Qin, J. *et al.* Estimation of incubation period distribution of COVID-19 using disease onset forward time: A novel cross-sectional and forward follow-up study. *Sci Adv* **6**, eabc1202 (2020).
11. Lauer, S. A. *et al.* The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Ann. Intern. Med.* **172**, 577–582 (2020).
12. Young, S. *et al.* Clinical Evaluation of BD Veritor SARS-CoV-2 Point-of-Care Test Performance

- Compared to PCR-Based Testing and versus the Sofia 2 SARS Antigen Point-of-Care Test. *Journal of Clinical Microbiology* **59**, e02338–20 (2021).
13. Abbott. *BinaxNOW COVID-19 Ag CARD*. <https://www.fda.gov/media/141570/download>.
  14. Pollock, N. R. *et al.* Performance and Implementation Evaluation of the Abbott BinaxNOW Rapid Antigen Test in a High-throughput Drive-through Community Testing Site in Massachusetts. doi:10.1101/2021.01.09.21249499.
  15. AccessBio. *CareStart COVID-19 Antigen test*. <https://www.fda.gov/media/142919/download>.
  16. Pollock, N. R. *et al.* Performance and Operational Evaluation of the Access Bio CareStart Rapid Antigen Test in a High-throughput Drive-through Community Testing Site in Massachusetts. *Open Forum Infect Dis* (2021) doi:10.1093/ofid/ofab243.
  17. *Celltrion DiaTrust™ COVID-19 Ag Rapid Test*. <https://www.fda.gov/media/147694/download>.
  18. Luminostics. *Clip COVID Rapid Antigen Test*. <https://www.fda.gov/media/144256/download>.
  19. Ellume. *Ellume COVID-19 Home Test*. <https://www.fda.gov/media/144592/download>.
  20. DiaSorin. *Liaison SARS-CoV-2 Ag assay*. <https://www.fda.gov/media/147311/download>.
  21. [No title]. <https://www.fda.gov/media/141304/download>.
  22. [No title]. <https://www.fda.gov/media/141304/download>.
  23. Qorvo Biotechnologies. *Omnia SARS-CoV-2 Antigen*. <https://www.fda.gov/media/147578/download>.
  24. InBios. *SCoV-2 Ag Detect Rapid Test*. <https://www.fda.gov/media/148353/download>.
  25. Quanterix. *Simoa SARS-CoV-2 N Protein Antigen Test*. <https://www.fda.gov/media/144929/download>.
  26. Quidel. *Sofia SARS Antigen FIA*. <https://www.fda.gov/media/137885/download>.
  27. Pray, I. W. Performance of an Antigen-Based Test for Asymptomatic and Symptomatic SARS-CoV-2 Testing at Two University Campuses — Wisconsin, September–October 2020. *MMWR Morb. Mortal. Wkly. Rep.* **69**, (2021).
  28. Quidel. *Sofia 2 Flu + SARS Antigen*. <https://www.fda.gov/media/142704/download>.
  29. LifeSign. *Status COVID-19/Flu*. <https://www.fda.gov/media/145697/download>.

30. VITROS. *VITROS Immunodiagnostic Products SARS-CoV-2 Antigen Reagent Pack*.

<https://www.fda.gov/media/145073/download>.